blue 3D waveform render

Investors

Welcome to the iCAD Investors page.

iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com

2024 Investor Deck

Sign up to receive Investor Alerts.

Subscribe to receive investor alerts from iCAD, Inc.

Press Releases

October 16, 2024

iCAD to Participate in the LD Micro Main Event XVII

NASHUA, N.H. – October 16, 2024 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the LD Micro Main Event XVII on October…

October 3, 2024

iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024

NASHUA, N.H., PARIS, FRANCE, October 3, 2024 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, today announced its participation in the 72nd edition of the Journées Francophones de Radiologie (JFR) 2024 Meeting, taking place from October 4-7 in Paris, France….

September 11, 2024

iCAD to Participate in the iAccess Alpha Buyside Best Ideas Fall Conference 2024

NASHUA, N.H. – September 11, 2024 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the iAccess Alpha Buyside Best Ideas Fall Conference…

Recent Events & Earning Calls

009 – Graph Created with Sketch.

Investor Relations

Investor Contact:
John Nesbett | Rosalyn Christian
IMS Investor Relations
icad@imsinvestorrelations.com
Megaphone

Media Inquiries